Global Cancer Diagnostics Market Size, Competitive Analysis, Strategies and Forecast Upto 2022

January 2016 | 130 pages | ID: G5F39AFA9F7EN
Market Research Engine

Abstracts

Tumor is a hereditary malady driven by substantial or heritable transformations. Advancement of new DNA sequencing and cutting edge sequencing innovations are relied upon to have a huge effect in the treatment, administration and discovery of growth. Cutting edge disease diagnostics business sector is relied upon to witness a lucrative development amid the gauge period attributable to expanding applications as a consequence of mechanical headways in cutting edge tumor diagnostics, for example, improvement of computerized and new imaging modalities so as to break down X-beam mammograms. These advancements will enhance exactness in the screening of bosom growth, mechanical advancements in research center testing gadgets for the advancement of new malignancy biomarkers, for example, protein examines, hormone, and receptor will assist enhance the finding and treatment of tumor with better investigation of tissue test. Expanding advancements in the examination of cell free DNA and flowing growth cells in fringe blood will likewise help the screening of disease in high hazard people. Moreover, enhanced in situ hybridization and immunohistochemical stains make compelling identification of disease cells in biopsied tissue and fringe blood. Protein design identification and bioinformatics investigation of quality are additionally anticipated that would assist make disease determination productive and these headways will help the business sector interest for cutting edge growth finding in the following seven years.

The worldwide cutting edge disease diagnostics business sector is divided on the premise of finding by growth sign, by diagnostics capacity and by sort of investigation. Cutting edge growth finding business sector is partitioned into bosom, colorectal and proteomic disease. Colorectal tumor portion is relied upon to develop at a huge rate because of expanding frequencies of colorectal growth in the worldwide populace and expanding research concentrates on in the biotechnology business. Cutting edge disease determination market by sort of examination is isolated into sidekick indicative, screening/early discovery, checking/repeat and forecast. Moreover, on the premise of sort of investigation, NGS growth determination business sector is separated into genotyping, proteomics and quality expression. Expanding interest for noninvasive and high throughput diagnostics measures for prior discovery of malignancy and sub-atomic subtypes of tumors for auspicious analysis and treatment, creative innovative headways in advancements connected with cutting edge screening and determination, for example, ongoing polymerase chain response (RT-PCR), cutting edge catch advances, biochips and cutting edge sequencing give quick conclusion, exact and touchy instruments for treating disease patients are relied upon to fuel the business sector development in the following seven years. Moreover, expanding frequencies of distinctive sort of malignancies, for example, blood-conceived growths, sex-related tumors and strong tumors, headways being developed of tests for discovery of DNA, RNA methylation design and coursing nucleic corrosive atoms are additionally anticipated that would drive the interest for the cutting edge disease analysis market through to the 2022.

The land investigation of cutting edge disease diagnostics market isolates it into North America, Europe, Asia-Pacific, Latin America and MEA. In 2015, North America represented the biggest piece of the overall industry in 2015 attributable to expanding use of cutting edge growth diagnostics systems in disease research, expanding appropriation of ease and reduced NGS tumor diagnostics measures in clinical diagnostics and research labs, and expanding nature of base for lab and clinical exploration. Developing economies, for example, China and India in the Asia Pacific locale are required to develop at a noteworthy rate all through the figure period. This normal development is credited for by expanding interest for financially savvy and safe malignancy medications in the locale , expanding government and corporate interest in the biotechnology and biopharmaceutical segment, rising per capita salary of the populace, expanding improvement and generation of new biologics, genomic measures, and sedates, growing restorative treatment for tumor analysis, expanding middle age of the populace and expanding concentrate on pulling in worldwide and residential players in the business sector. The worldwide cutting edge malignancy diagnostics business sector is exceedingly focused inferable from development of new contestants in the business sector and the vicinity of entrenched firms. The key members in the cutting edge growth diagnostics market incorporate GE Healthcare, Abbott Laboratories, Allegro Diagnostics Corp., Siemens Healthcare, Agilent Technologies Inc., Becton Dickinson and Co., QIAGEN N.V., Affymetrix Inc., Thermo Fisher Scientific Inc., Life Technologies Corp., Cepheid Inc., bioMerieux SA, Johnson and Johnson, Fluidigm Corp., PerkinElmer Inc., Randox Laboratories Ltd., SomaLogic Inc., Luminex Corp., Radient Pharmaceuticals Corp., Roche Holding Ltd, Quest Diagnostics Inc., Asuragen Inc., AVIVA Biosciences Corp., Illumina Inc., Veridex LLC, Nanosphere Inc., A. Menarini Diagnostics S.r.l., Fujirebio Diagnostics Inc. also, Oncolys BioPharma Inc

Cancer Diagnostics Market, by Method:

• Biopsy
• Endoscopy
• Tumor Biomarker Tests
• Imaging

Major geographies analyzed under this research report are:

• Europe
• North America
• Asia-Pacific
• Rest of the World

This report gives you access to decisive data such as:

• Market growth drivers
• Factors limiting market growth
• Current market trends
• Market structure
• Market projections for the coming years

Key highlights of this report :

Overview of key market forces propelling and restraining market growth :

• Up-to-date analyses of market trends and technological improvements
• Pin-point analyses of market competition dynamics to offer you a competitive edge
• An analysis of strategies of major competitors
• An array of graphics and SWOT analysis of major industry segments
• Detailed analyses of industry trends
• A well-defined technological growth map with an impact-analysis
• Offers a clear understanding of the competitive landscape and key product segments

Contents

1 INTRODUCTION

1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
  1.3.1 Markets Covered
  1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders

2 RESEARCH METHODOLOGY

  2.1.1 Research Methodology Steps
  2.1.2 Secondary and Primary Research Methodology
    2.1.2.1 Secondary Research
    2.1.2.2 Key Data From Secondary Sources
    2.1.2.3 Primary Research
    2.1.2.4 Key Industry Insights
  2.1.5 Key Data From Primary Sources
  2.1.6 Key Insights From Primary Sources
  2.1.7 Market Size Estimation Methodology
  2.1.8 Market Forecast Methodology
  2.1.9 Market Data Validation and Triangulation
  2.1.10 Assumptions for the Study

3 EXECUTIVE SUMMARY

3.1 Introduction
3.2 Current Scenario
3.3 Future Outlook
3.4 Conclusion

4 PREMIUM INSIGHTS

4.1 Global Cancer Diagnostics Market
4.2 Regional Snapshot of the Cancer Diagnostics Market
4.3 Cancer Diagnostics Market, By Technology (2015 vs. 2022)

5 MARKET OVERVIEW

5.1 Key Findings
5.2 Introduction
5.3 Market Dynamics
  5.3.1 Drivers
    5.3.1.1 Rising Prevalence of Cancer
    5.3.1.2 Technological Advancements
    5.3.1.3 Initiatives Undertaken By Governments and Global Health Organizations to Spread Awareness About Cancer
    5.3.1.4 Growth in the Number of Private Diagnostic Centers
    5.3.1.5 Public-Private Partnerships to Enhance the Infrastructure of Diagnostic Imaging Centers
    5.3.1.6 Fda Support for Biomarker Development
    5.3.1.7 Launch of New Flow Cytometry Reagents for Diagnostics and Drug Discovery
  5.3.2 Restraints
    5.3.2.1 High Capital Investments & Low Benefit-Cost Ratio for Biomarkers
    5.3.2.2 Shortage of Helium
    5.3.2.3 High Cost of Diagnostic Imaging Systems Affecting Their Rate of Adoption in Emerging Markets
    5.3.2.4 Risk of High Radiation Exposure Likely to Limit the Usage of CT Scanners
    5.3.2.5 Dearth of Skilled and Experienced Personnel
  5.3.3 Opportunities
    5.3.3.1 Personalized Medicine
    5.3.3.2 Development of Mass Cytometry and the Combination of Cell-And Bead-Based Flow Cytometry Technologies
    5.3.3.3 Companion Diagnostics
    5.3.3.4 Improving Healthcare Infrastructure in Emerging Markets
    5.3.3.5 Miniaturized and Technologically Advanced Devices
  5.3.4 Challenges
    5.3.4.1 Stringent Regulatory Guidelines
    5.3.4.2 Hospital Budget Cuts A Key Challenge to Market Players
    5.3.4.3 Increasing Adoption of Refurbished Diagnostic Imaging Systems

6 GLOBAL CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY

6.1 Introduction
6.2 Platform-Based Diagnostics
  6.2.1 Polymerase Chain Reaction (PCR)
  6.2.2 in Situ Hybridization (ISH)
  6.2.3 Immunohistochemistry (IHC)
  6.2.4 Next-Generation Sequencing (NGS)
  6.2.5 Microarrays
  6.2.6 Flow Cytometry
  6.2.7 Other Technologies
6.3 Instrument-Based
  6.3.1 Diagnostic Imaging
    6.3.1.1 Magnetic Resonance Imaging (MRI)
    6.3.1.2 Computed Tomography (Ct)
    6.3.1.3 Positron Emission Tomography (PET)
      6.3.1.3.1 Standalone Positron Emission Tomography
      6.3.1.3.2 Hybrid Positron Emission Tomography
    6.3.1.4 Mammography
    6.3.1.5 Ultrasound
  6.3.2 Biopsies

7 GLOBAL CANCER DIAGNOSTICS MARKET, BY APPLICATION

7.1 Introduction
  7.1.1 Breast Cancer
  7.1.2 Lung Cancer
  7.1.3 Colorectal Cancer
  7.1.4 Melanoma
  7.1.5 Other Cancers

8 MARKET, BY END USER

9 CANCER DIAGNOSTICS MARKET, BY REGION

9.1 Introduction
9.2 North America
  9.2.1 U.S.
    9.2.1.1 Government Initiatives
    9.2.1.2 Increase in Cancer Incidence
  9.2.2 Canada
    9.2.2.1 High Incidence of Cancer
    9.2.2.2 Government Funding
9.3 Europe
  9.3.1 Funding for Cancer Diagnostics Research
  9.3.2 Eu-5 (U.K., Germany, France, Italy, Spain)
    9.3.2.1 Strong Government Support
    9.3.2.2 Research Collaborations
    9.3.2.3 Increase in Diagnostic Imaging Centers
    9.3.2.4 Rising Public and Private Investments
  9.3.3 Rest of Europe (RoE)
    9.3.3.1 Aging Population
    9.3.3.2 Conferences Boosting Awareness
    9.3.3.3 Government Investments in Russia
9.4 Asia
    9.4.1.1 China
      9.4.1.1.1 Expansion of International Players
      9.4.1.1.2 Aging Population and Increasing Cancer Incidence
    9.4.1.2 Japan
      9.4.1.2.1 Aging Population and High Healthcare Expenditure in Japan
    9.4.1.3 India
      9.4.1.3.1 Increasing Focus of International Players on India
    9.4.1.4 Rest of Asia
      9.4.1.4.1 Presence of International Players Boosting Market Growth
9.5 Rest of the World (RoW)
    9.5.1.1 Government Initiatives Boosting Demand for Cancer Diagnostics
    9.5.1.2 Aging Population, Presence of International Players
    9.5.1.3 Increase in Cancer Incidences and Rising Government Expenditure
    9.5.1.4 Government Initiatives to Improve Healthcare Infrastructure

10 COMPETITIVE LANDSCAPE

10.1 Overview
10.2 Market Share Analysis
10.3 Competitive Situation and Trends
  10.3.1 Collaborations/Agreements/Partnerships/Alliances
  10.3.2 New Product Launches
  10.3.3 Acquisitions
  10.3.4 Expansion
  10.3.5 Others

11 COMPANY PROFILES

11.1 Introduction
11.3 Becton, Dickinson and Company
  11.3.1 Business Overview
  11.3.2 Product Portfolio
  11.3.3 Key Strategy
  11.3.4 Recent Developments
11.4 GE Healthcare (A Subsidiary of General Electric Company)
  11.4.1 Business Overview
  11.4.2 Product Portfolio
  11.4.3 Key Strategy
  11.4.4 Recent Developments
11.5 Abbott
  11.5.1 Business Overview
  11.5.2 Product Portfolio
  11.5.3 Key Strategy
  11.5.4 Recent Developments
11.6 Roche
  11.6.1 Business Overview
  11.6.2 Product Portfolio
  11.6.3 Key Strategy
  11.6.4 Recent Developments
11.7 Thermo Fisher Scientific, Inc.
  11.7.1 Business Overview
  11.7.2 Thermo Fisher Scientific, Inc.: Company Snapshot
  11.7.3 Product Portfolio
  11.7.4 Key Strategy
  11.7.5 Recent Developments
11.8 Agilent Technologies, Inc.
  11.8.1 Business Overview
  11.8.2 Agilent Technologies, Inc.: Company Snapshot
  11.8.3 Product Portfolio
  11.8.4 Key Strategy
  11.8.5 Recent Developments
11.9 Illumina, Inc.
  11.9.1 Business Overview
  11.9.2 Product Portfolio
  11.9.3 Key Strategy
  11.9.4 Recent Developments
11.10 Siemens Healthcare
  11.10.1 Business Overview
  11.10.2 Product Portfolio
  11.10.3 Key Strategy
  11.10.4 Recent Developments
11.11 C.R. Bard, Inc.
  11.11.1 Business Overview
  11.11.2 Product Portfolio
  11.11.3 Key Strategy
  11.11.4 Recent Developments

12 APPENDIX

12.1 Discussion Guide
12.2 Available Customizations
12.3 Related Reports
12.4 Introducing RT: Real-Time Market Intelligence
List of Tables
Table 1 Rising Prevalence of Cancer is Driving the Growth of the Cancer Diagnostics Market
Table 2 High Capital Investment Restraining the Growth of this Market
Table 3 Emerging Markets Present an Array of Opportunities for the Growth of this Market
Table 4 Stringent Regulatory Guidelines are A Major Challenge in the Cancer Diagnostics Market
Table 5 Global Cancer Diagnostics Market Size, By Technology, 2015–2022($Million)
Table 6 Global Market Size, By Technology, 2015–2022($Million)
Table 7 Market Size for Platform-Based Diagnostics, By Region, 2015–2022($Million)
Table 8 Global Cancer Diagnostics Market Size for PCR, By Region, 2015–2022($Million)
Table 9 Global Cancer Diagnostics Market Size for PCR, By Application, 2015–2022($Million)
Table 10 Cancer Diagnostics Market Size for in Situ Hybridization, By Region, 2013-2020 ($Million)
Table 11 Global Market Size for in Situ Hybridization, By Application, 2015–2022($Million)
Table 12 Market Size for Immunohistochemistry, By Region, 2015–2022($Million)
Table 13 Global Cancer Diagnostics Market Size for Immunohistochemistry, By Application, 2015–2022($Million)
Table 14 Market Size for NGS, By Region, 2015–2022($Million)
Table 15 Global Market Size for NGS, By Application, 2015–2022($Million)
Table 16 Cancer Diagnostics Market Size for Microarrays, By Region, 2015–2022($Million)
Table 17 Global Market Size for Microarrays, By Application, 2015–2022($Million)
Table 18 Cancer Diagnostics Market Size for Flow Cytometry, By Region, 2015–2022($Million)
Table 19 Global Market Size for Flow Cytometry, By Application, 2015–2022($Million)
Table 20 Market Size for Other Technologies, By Region, 2015–2022($Million)
Table 21 Global Market Size for Other Technologies, By Application, 2015–2022($Million)
Table 22 Global Market Size, By Technology, 2015–2022($Million)
Table 23 Cancer Diagnostics Market Size for Diagnostic Imaging, By Product, 2015–2022($Million)
Table 24 Market Size for Diagnostic Imaging, By Region, 2015–2022($Million)
Table 25 Global Market Size for Imaging, By Application, 2015–2022($Million)
Table 26 Cancer Diagnostics Market Size for MRI, By Region, 2015–2022($Million)
Table 27 Cancer Diagnostics Market Size for CT, By Region, 2015–2022($Million)
Table 28 Market Size for PET, By Product, 2015–2022($Million)
Table 29 Cancer Diagnostics Market Size for PET, By Region, 2015–2022($Million)
Table 30 Cancer Diagnostics Market Size for Standalone PET, By Region, 2015–2022($Million)
Table 31 Market Size for Hybrid PET, By Region, 2015–2022($Million)
Table 32 Market Size for Mammography, By Region, 2015–2022($Million)
Table 33 Cancer Diagnostics Market Size for Ultrasound, By Region, 2015–2022($Million)
Table 34 Cancer Diagnostics Market Size for Biopsy, By Region, 2015–2022($Million)
Table 35 Global Market Size for Biopsy, By Application, 2015–2022($Million)
Table 36 Global Market Size, By Application, 2015–2022($Million)
Table 37 Market Size for Breast Cancer, By Region, 2015–2022($Million)
Table 38 Cancer Diagnostics Market Size for Lung Cancer, By Region, 2015–2022($Million)
Table 39 Market Size for Colorectal Cancer, By Region, 2015–2022($Million)
Table 40 Market Size for Melanoma, By Region, 2015–2022($Million)
Table 41 Cancer Diagnostics Market Size for Other Cancers, By Region, 2015–2022($Million)
Table 42 North America Market, By Country, 2015–2022($Million)
Table 43 North America: Market, By Technology, 2015–2022($Million)
Table 44 North America: Cancer Diagnostics Platform-Based Market, By Technology, 2015–2022($Million)
Table 45 North America: Cancer Diagnostics Instrument-Based Market, By Technology, 2015–2022($Million)
Table 46 North America: Market, By Application, 2015–2022($Million)
Table 47 U.S.: Market, By Technology, 2015–2022($Million)
Table 48 U.S.: Cancer Diagnostics Platform-Based Market, By Technology, 2015–2022($Million)
Table 49 U.S.: Cancer Diagnostics Instrument-Based Market, By Technology, 2015–2022($Million)
Table 50 Canada: Market, By Technology, 2015–2022($Million)
Table 51 Canada: Cancer Diagnostics Platform-Based Market, By Technology, 2015–2022($Million)
Table 52 Canada: Cancer Diagnostics Instrument-Based Market, By Technology, 2015–2022($Million)
Table 53 Europe: Market, By Region, 2015–2022($Million)
Table 54 Europe: Cancer Diagnostics Market, By Technology, 2015–2022($Million)
Table 55 Europe: Cancer Diagnostics Platform-Based Market, By Technology, 2015–2022($Million)
Table 56 Europe: Cancer Diagnostics Instrument Market, By Technology, 2015–2022($Million)
Table 57 Europe: Cancer Diagnostics Market, By Application, 2015–2022($Million)
Table 58 EU-5: Market, By Technology, 2015–2022($Million)
Table 59 EU-5: Cancer Diagnostics Platform-Based Market, By Technology, 2015–2022($Million)
Table 60 EU-5: Cancer Diagnostics Instrument-Based Market, By Technology, 2015–2022($Million)
Table 61 RoE: Market, By Technology, 2015–2022($Million)
Table 62 RoE: Cancer Diagnostics Platform-Based Market, By Technology, 2015–2022($Million)
Table 63 RoE: Cancer Diagnostics Instrument-Based Market, By Technology, 2015–2022($Million)
Table 64 Asia: Market, By Country, 2015–2022($Million)
Table 65 Asia: Market, By Technology, 2015–2022($Million)
Table 66 Asia: Cancer Diagnostics Platform-Based Market, By Technology, 2015–2022($Million)
Table 67 Asia: Cancer Diagnostics Instrument-Based Market, By Technology, 2015–2022($Million)
Table 68 Asia: Market, By Application, 2015–2022($Million)
Table 69 China: Market, By Technology, 2015–2022($Million)
Table 70 China: Cancer Diagnostics Platform-Based Market, By Technology, 2015–2022($Million)
Table 71 China: Cancer Diagnostics Instrument-Based Market, By Technology, 2015–2022($Million)
Table 72 Japan: Market, By Technology, 2015–2022($Million)
Table 73 Japan: Cancer Diagnostics Platform-Based Market, By Technology, 2015–2022($Million)
Table 74 Japan: Cancer Diagnostics Instrument-Based Market, By Technology, 2015–2022($Million)
Table 75 India: Market, By Technology, 2015–2022($Million)
Table 76 India: Cancer Diagnostics Platform-Based Market, By Technology, 2015–2022($Million)
Table 77 India: Cancer Diagnostics Instrument-Based Market, By Technology, 2015–2022($Million)
Table 78 RoA: Market, By Technology, 2015–2022($Million)
Table 79 RoA: Cancer Diagnostics Platform-Based Market, By Technology, 2015–2022($Million)
Table 80 RoA: Cancer Diagnostics Instrument-Based Market, By Technology, 2015–2022($Million)
Table 81 RoW: Market, By Technology, 2015–2022($Million)
Table 82 RoW: Cancer Diagnostics Platform-Based Market, By Technology, 2015–2022($Million)
Table 83 RoW: Cancer Diagnostics Instrument-Based Market, By Technology, 2015–2022($Million)
Table 84 RoW: Market, By Application, 2015–2022($Million)
Table 85 Collaborations/Agreements/Partnerships/Alliances, 2015-2018
Table 86 New Product Launches, 2015–2018
Table 87 Acquisitions, 2015–2018
Table 88 Expansions, 2015–2018
Table 89 Other Strategies, 2015–2018